&#xa0;
defaultWritten evidence submitted by defaultAstraZenecadefault (AMR0018)default&#xa0;defaultExecutive summarydefault&#xa0;default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
defaultAbout AstraZenecadefault&#xa0;
default&#xa0;defaultTerms of Referencedefault&#xa0;
defaultHow has antimicrobial resistance developed in the past decade?
default&#xa0;
default&#xa0;
default&#xa0;
defaultWhat are the gaps in our knowledge about antimicrobial resistance?
default&#xa0;
default&#xa0;
defaultIs there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified?
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
defaultWhat measures (including behavioural change) 
defaulthave been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens?
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
defaultWhat global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
defaultWhat are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?
default&#xa0;
default&#xa0;
default&#xa0;
default&#xa0;
defaultRecommendations for actiondefault&#xa0;
default&#xa0;
default&#xa0;default&#xa0;default&#xa0;
default&#xa0;default&#xa0;
default&#xa0;
default&#xa0;defaultNovember 2013
default&#xa0;default&#xa0;default&#xa0;default&#xa0;default&#xa0;default&#xa0;default&#xa0;defaultREFERENCESdefault&#xa0;
default&#xa0;
default&#xa0;
defaultAnnual Report of the Chief Medical Officer Volume Two, 2011. Infections and the rise of antimicrobial resistance. Available at: 
defaulthttps://www.gov.uk/government/uploads/system/uploads/attachment_data/file/138331/CMO_Annual_Report_Volume_2_2011.pdf
default. Accessed September 2013
default World Health Organization Regional Office for Europe. Self-prescription of antibiotics boosts superbugs epidemic in the European Region. November 16, 2012. Available at: 
defaulthttp://www.euro.who.int/en/what-we-publish/information-for-the-media/sections/latest-press-releases/self-prescription-of-antibiotics-boosts-superbugs-epidemic-in-the-european-region
default. Accessed September 2013
default Office of Health Economics. New drugs to tackle antimicrobial resistance: analysis of EU policy options. April 2011. Available for download from: 
defaulthttp://www.ohe.org/page/index.cfm
default. Accessed September, 2013
default Infectious Diseases Society of America (IDSA), Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, et al. Combating Antimicrobial Resistance: Policy Recommendations To Save Lives. Clin Infect Dis 2011:52(Suppl 5):S397-428
default Projan S. (2003) Why big pharma is getting out of AB discovery, Current Opinion in Microbiology 2003, 6:427-430
default Smith R and Coast J, The true cost of antimicrobial resistance, British Medical Journal 2013;346
defaulthttp://www.bmj.com/content/346/bmj.f1493
default 
default Sally Davies, The drugs don’t work, Sunday Times, 15 September 2013
defaulthttp://www.thesundaytimes.co.uk/sto/newsreview/features/article1313446.ece
default 
default Innovative
default Medicines Initiative, 
default9th Call for Proposals 2013
default, July 2013. 
defaulthttp://www.imi.europa.eu/webfm_send/914
default Health Protection Agency, Healthcare-Associated Infection and Antimicrobial Resistance: 2010-2011, August 2012 
defaulthttp://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317136146912
default 
default Department of Health, UK Five Year Antimicrobial Resistance Strategy 2013 to 2018, 10 September 2013. Available at 
defaulthttps://www.gov.uk/government/uploads/system/uploads/attachment_data/file/238872/20130902_UK_5_year_AMR_strategy_FINAL.pdf
default House of Commons Science and Technology Committee,  Uncorrected Transcript Of Oral Evidence from the Chief Medical Officer, Department of Health, HC 921-I, Published 11
defaultth
default February 2013
defaulthttp://www.publications.parliament.uk/pa/cm201213/cmselect/cmsctech/uc921-i/uc92101.htm
default 
default World Health Organisation. World Health Day 2011: Urgent action necessary to safeguard drug treatments. News Release. 06 April 2011 
defaulthttp://www.who.int/mediacentre/news/releases/2011/whd_20110406/en/index.html
default World Economic Forum, Global Risks 2013: Eighth Edition. Published 2013. Available at 
defaulthttp://reports.weforum.org/global-risks-2013/view/risk-case-1/the-dangers-of-hubris-on-human-health/
default Accessed September 2013
default Infectious Diseases Society of America, The 10 x 20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020, Clin Infect Dis. (2010) 50 (8): 1081-1083
defaulthttp://cid.oxfordjournals.org/content/50/8/1081.full.pdf+html
default 
default Elaine A Irving presentation, New Drugs for Bad Bugs – Regulatory aspects in Innovative Medicines Initiative projects, November 2010
defaulthttp://www.efpia.eu/uploads/Modules/Documents/nd4bb_overview_jan_2013.pdf
default 
default Pew Health Group, Fact sheet:  The Generating Antibiotic Incentives Now Act of 2011, 20 September 2011 
defaulthttp://www.pewtrusts.org/uploadedFiles/wwwpewtrustsorg/Fact_Sheets/Antibiotics_and_Innovation/Antibiotics_GAIN_FactSheet.pdf
default BBC News Online, Antibiotics resistance 'as big a risk as terrorism' - medical chief, 11 March 2013
defaulthttp://www.bbc.co.uk/news/health-21737844
default